Why are south asians at higher risk for heart disease? new study looks at stem cells for answers
NCT ID NCT06769347
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This observational study is recruiting 120 adults without diabetes or heart disease to compare blood vessel-forming stem cells between people of South Asian and European origins. Researchers want to see if differences in these stem cells help explain why South Asians face a higher risk of cardiovascular disease. Participants will provide blood samples to measure specific cell types. The study does not test any treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help explain why South Asian people have higher heart disease risk, pointing toward future prevention strategies.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not find clear differences, and results may not directly lead to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants will be identified from primary care and cardiology outpatient clinics in the Greater Toronto Area using paper-based and electronic medical records.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adults 18 years of age or older of South Asian origin or European origin as defined by the following: i. South Asian defined as any individual who identifies as Anglo-Indian, Bangladeshi, Bengali, Bhutanese, Goan, Gujarati, Indian, Jatt, Kashmiri, Maharashtrian, Malayali, Nepali, Pakistani, Punjabi, Sindhi, Sinhalese, Sri Lankan, Tamil, Telugu, or other South Asian origins. ii. European Origin defined as any individual who identifies as from western Europe, northern Europe, southern Europe, eastern Europe or other European origins. 2. Willing and able to provide written informed consent and comply with study requirements 3. Must fulfill the following exclusion criteria: Exclusion Criteria: 1. No previous diagnosis of type 2 diabetes 2. Any previous CV events such as: 1. Prior myocardial infarction 2. Coronary revascularization 3. Coronary artery disease, peripheral artery disease, cerebrovascular disease 3. Any life-threatening disease expected to result in death within the next 2 years 4. Any malignancy not considered cured (except basal cell carcinoma of the skin). A subject is considered cured if there has been no evidence of cancer recurrence for the 5 years prior to screening 5. Known severe liver disease (e.g. Non-alcoholic fatty liver disease, chronic liver disease, liver cirrhosis, etc.) 6. White blood cell count ≥ 15 x 10\^9/L 7. Active infectious disease requiring antibiotic or anti-viral agents 8. Known acquired immunodeficiency syndrome such as HIV 9. On oral steroid therapy (e.g. prednisone) or other immunosuppressive agents (e.g. methotrexate) 10. Treated autoimmune disorder
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular diseases risk are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Diagnostic Assessment Centre
Scarborough Village, Ontario, M1S4N6, Canada
-
Langstaff Medical Centre
Woodbridge, Ontario, L4L 0K8, Canada
-
Markham HealthPlex Medical Centre
Markham, Ontario, L3S 0A2, Canada
-
Marlee Medical Centre
North York, Ontario, M6B4B8, Canada
-
North York Diagnostic and Cardiac Centre
North York, Ontario, M6B 3H7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.